We are currently conducting a research study involving 10 patients who are receiving immunotherapy as the first-line treatment. 

The study aims to apply iDxGate IO to predict treatment responsiveness through mutation and biomarker exploration. 

Over the course of one year, we will monitor patient outcomes to derive the iDxGate IO algorithm specifically for metastatic lung cancer.

Lung cancer holds the top position in both global incidence and mortality rates among all cancer types. 

While various treatment approaches are applied, there remains a significant unmet need in the diagnosis for treatment application.

iDxGate strives to address these needs by establishing a diagnostic method. 

We plan to release the results of this study in the first half of next year and continue with expanded clinical trials.